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A bovine pineal acid extract displays a vasotocin-like bioactivity in several bioassays, and is recognized by 
antibodies against the Pro-Arg-Gly-amide ending common to vasopressin and vasotocin. By using molecu- 
lar sieve filtration and reversed-phase HPLC, a vasopressin- and oxytocin-like peptide was isolated from 
this pineal preparation, while no evidence for a vasotocin-like peptide was obtained. The isolated neuropep- 
tides contain a modified amino acid at position 2. This structural difference with authentic pituitary vaso- 
pressin and oxytocin may alter their biological and immunological properties, which have been interpreted 
as vasotocin-like, and thus underlies the controversy concerning the existence of vasotocin in the mamma- 
lian pineal gland. 
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1. INTRODUCTION 
The report of Milcu et al. [I] which described a 
peptide in bovine pineal glands with the biological 
and chromatographic properties of [8-argininel- 
vasotocin (AVT) created the controversy on the 
existence of AVT as a mammalian pineal peptide. 
Over the last 20 years data from biological, im- 
munological and chemical studies have been inter- 
preted as evidence for or against the presence of 
this alleged peptide in the mammalian pineal organ 
(review [2]). The repeatedly reported detection of 
AVT has mainly been based on a vasotocin-like ac- 
tivity and immunoreactivity [1,3-51, while a 
number of reports have consistently disclaimed the 
presence of AVT in the mammalian pineal on the 
grounds of immunological or chromatographic 
properties [6-81. Neacsu [9] prepared a peptidic 
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fraction (termed E5) with antigonadotropic activi- 
ty from bovine pineal glands. The author conclud- 
ed that ES consisted of 14 amino acids including 
those of AVT [9]. This bovine pineal preparation 
displayed AVT-like bioactivity in several bioassays 
[8,10], and reacted with antisera against Pro-Arg- 
Gly-amide endings, the carboxyl-terminal tripep- 
tide common to AVT and [8_arginine]vasopressin 
(AVP) [ll]. In contrast, P&et et al. [8] failed to 
detect any AVT, AVP or oxytocin (OXT) in the 
pineal E5 extract by radioimmunoassays (RIA). In 
the scope of our work on the pineal gland we 
purified neuropeptides from the bovine ES 
preparation. Here we report the isolation and 
characterization of pineal AVP- and OXT-like 
peptides, while no evidence for AVT was obtained. 
It is shown that AVP- and OXT-like peptides from 
the bovine pineal contain a modified amino acid. 
This structural difference with the authentic 
hypophyseal neuropeptides AVP-( l-9) and OXT- 
(l-9) may alter their biological and immunological 
properties, which may have been interpreted as 
AVT-like and thus underlies the controversy con- 
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cerning the existence of AVT as a mammalian 
pineal peptide. 
2. MATERIALS AND METHODS 
The preparation of the bovine pineal acid extract 
(E5) is described elsewhere [9], and was obtained 
from Dr P. P&et (NIH, Amsterdam). Purification 
of neurohypophyseal hormone-like structures and 
their dissociation from accompanying carrier pro- 
teins were performed by gel filtration in formic 
acid as in [12]. Details of the procedures and an- 
tigenic properties of the radioimmunoassays have 
been described [13-161. Reversed-phase HPLC 
was carried out with a Perkin-Elmer model series 
4LC system; the HPLC columns were described in 
[ 11,171. The gel isoelectric focusing was performed 
on polyacrylamide gel slabs (10 x 10 x 0.1 cm) 
containing 2% Servalyte AG 2-11 (Serva, 
Heidelberg) [ 181. The amino acid composition of 
the isolated neuropeptides was determined by per- 
formic acid oxidation and acid hydrolysis (6 M 
HCI containing O.lYo thioglycolic acid, 16 h at 
1 lO’C), followed by o-phthaldialdehyde (OPT) 
derivatization and separation of the OPT-amino 
acids by HPLC [19,20]. 
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3. RESULTS 
Fig.lA shows representative dilution curves of 
AVP determination in the bovine pineal E5 
preparation, using the AVP antiserum raised 
against he COOH-terminal tripeptide ending com- 
mon to AVP-(l-9) and AVT-(I-9) [13]. Using 
radioimmunoassays for the 20-membered ring 
structure of AVP [ 141 and AVT [ 151, only amounts 
of immunoreactive AVP-like material could be 
measured in the extract (fig.lB). Antigenic 
similarities of pineal OXT-like constituents with 
standard OXT-( l-9) could also be measured in the 
RIA for OXT [14]. 
A portion corresponding to 20.0 mg protein of 
the bovine pineal E5 preparation was fractionated 
by gel filtration on a Sephadex G-100 column 
eluted in 0.1 M formic acid containing 0.1% (w/v) 
bovine serum albumin (fig.2A), followed by 
Sephadex G-50 superfine filtration in 1% formic 
acid of the peptide pool with an AVP and OXT im- 
munoreactivity (fig.2B). This material was retain- 
ed on Sep-pak and could be eluted with 80% 
methanol. By this procedure, the immunoreactive 
material was considerably purified and concen- 
trated. Final purification was achieved by subse- 
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Fig.1. Standard curve and cross-reactivity curves of the bovine pineal E5 extract for the vasopressin RIAs (see text). 
(A) Log-logit plot of dilution and standard curves using the AVP antibody raised against the Pro-Arg-Gly-amide ending 
[13]. (B) Inhibition of binding to “‘I-AVP to the AVP antiserum for the ring structure of the neuropeptide [14] by 
pineal compounds. Each point of the curves represents the mean of three determinations. B, 070 binding observed; Bo, 
Vo initial binding; F, % non-binding. 
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Fig.2. Fractionation of the bovine pineal ES fraction by 
molecular sieve filtration. (A) 20.0 mg bovine pineal ES 
dissolved in 2.0 ml of 0.1 M formic acid was applied on 
Sephadex G-100 (1.6 x 58 cm) run in 0.1 M formic acid 
containing 0.1% (w/v) BSA at a flow rate of 80 ml/h; 
fraction size, 2.0 ml. The presence of neurophysin and 
peptides with a COOH-terminal Pro-Arg-Gly(NHz) 
sequence was assayed by radioimmunoassay [13,16]. 
Arrows indicate elution positions of standard AVP- 
(l-9) and bovine pituitary neurophysin (NpII). (B) 
Rechromatography of the peptide pool with AVP 
immunoreactivity (fractions 42-68; A) on Sephadex 
G-50 superfine (1.6 x 98 cm) eluted with 1% (V/V) 
formic acid at 1.0 ml/h; fraction size, 1.0 ml. The 
neurohormone-like activity assayed by RIA in the 
indicated area (fractions 129-166) was collected for 
subsequent purification on HPLC. 
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Fig.3. Final purification of bovine pineal neuropeptides 
by reversed-phase HPLC. The material obtained from 
the immunoreactive AVP- and OXT-like pool (fractions 
129-166, fig.2B) was passed through a Sep-pak Cl8 
cartridge eluted with methanol. The dried methanol 
effluent was dissolved in 10 mM ammonium acetate (pH 
4.15) and applied through multiple injections to a 
pBondapak Cl8 column (0.39 x 30 cm). (A) 
Fractionation of 0.9 nmol AVP- and 1.1 nmol OXT-like 
material by isocratic elution with 0.15% (v/v) acetic acid 
in methanol/l0 mM ammonium acetate (pH 4.15) 
(36: 64) at a flow rate of 2.0 ml/min. Component III 
was used for structural analysis. (B) Rechromatography 
of component I (A) by isocratical elution with 0.15% 
(v/v) acetic acid in methanol110 mM ammonium acetate 
(pH 4.15) (1 : 3) at a flow rate of 2.0 ml/min. 
Component IA was subsequently submitted to amino 
acid analysis. Arrows indicate elution positions of 
synthetic peptides under the same conditions as for (A) 
and (B) on a separate FBondapak column and served as 
a reference chromatogram. 
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Fig.4. Gel isoelectric focusing in a 5% polyacrylamide 
gel slab containing 2% carrier ampholytes in the pH 
range 2-12 [18]. (Top) Synthetic AVP (1.0 ng 
immunoreactive AVP applied, recovery 86%). (Bottom) 
Bovine pineal component IA (fig.3B) (7.0 ng AVP-like 
material by RIA, recovery 86%), with subsequent RIA 
for AVP (ng/2 mm slice). Arrow indicates sample 
application spot. 
quent reversed-phase HPLC steps on apBondapak 
Cl8 column [17], and yielded approx. 4.5 nmol 
AVP-like peptide and 5.6 nmol OXT-like peptide 
by radioimmunoassay [ 13- 151. These natural com- 
ponents, detectable in the HPLC profile by UV ab- 
sorbance at 210 nm (fig.3), had comparable 
retention times to synthetic AVP-(1-9) and OXT- 
(l-9) in three solvent systems, and showed that the 
material was pure. An AVT-like peptide remained 
undetectable above background levels by RIA [ 151 
during all chromatographic purification steps. Us- 
ing parallel polyacrylamide gel slab isoelectric 
focusing patterns of immunoreactive AVP-like 
I 
material after HPLC (component IA, fig.3B) and 
synthetic AVP-( l-9) yielded nearly coincidental 
isoelectric points at pH 9.2-9.4 (fig.4). 
The isolated peptides were further analyzed for 
amino acid composition after performic acid ox- 
idation and acid hydrolysis by pre-column 
derivatization with OPT and reversed-phase 
HPLC [19,20]. The analysis showed that the 
isolated pineal AVP- and OXT-like peptides con- 
tained all the constituent amino acid residues in the 
molar ratios expected for authentic AVP-(l-9) 
and OXT-( l-9), respectively, except for tyrosine 
(fig.5). However, another OPT derivative was 
detected in the HPLC profile, which was not 
observed when synthetic AVP-(1-9) and OXT- 
(l-9) were oxidized and hydrolyzed in the same 
way, and did not correspond to any of the other 
common amino acids of peptide and protein 
hydrolysates in AVP-( l-9) and OXT-( l-9) (fig.5). 
The unknown OPT derivative, when calculated as 
a tyrosine residue, occurred in a molar ratio as ex- 
pected for tyrosine in AVP-( l-9) and OXT-( l-9) 
(fig.5). In order to obtain information about the 
structure of the unknown residue in the pineal 
neuropeptides, hydrolysates of several synthetic 
peptides with derivatized tyrosine residues and 
amino acids with structures related to tyrosine 
were analyzed by the OPT derivatization-HPLC 
method [20]. After oxidation and hydrolysis of 
cholecystokinin octapeptide, which is sulfated at 
the hydroxyl group of the tyrosine residue, and of 
the AVP antagonist [d(CH&,2-(O-methyl)- 
Tyr*]AVP [21], underivatized tyrosine was 
detected by amino acid analysis. Oxidation and 
hydrolysis of a-methyl-p-tyrosine and 3-methoxy- 
tyrosine failed to generate an OPT derivative with 
similar retention time to the unknown res$lue. 
DOPA (3_hydroxytyrosine), which is a natural in- 
termediate of dopamine biosynthesis from 
tyrosine, eluted well before tyrosine on HPLC. 
In order to evaluate a possible artifactual 
derivatization of the tyrosine residue in pineal 
AVP and OXT during tissue extraction 
[[3H]Tyr2]OXT (1 &i; spec. act. 20 Ci/mmol) 
was added to 15 mg wet wt pineal tissue, and ex- 
tracted with water or 1 M acetic acid and left at 
room temperature for 30 min. The extract was 
lyophilized and fractionated by reversed-phase 
HPLC using a methanol/ammonium acetate 
(10 mM, pH 4.15) system [19]. The [[3H]Tyr2]- 
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Fig.5. Elution profiles of OPT derivatives of amino acids on a CP-Spher Cl8 column (0.46 x 25.0 cm) by HPLC. (A) 
Upper: amino acid analysis of 500 pmol synthetic 1-desamino-D-arginine’-AVP (DDAVP); lower: separation of OPT 
derivatives of residues from pineal AVP-like material (peak IA, fig.3B). (B) Upper: analysis of 500 pmol synthetic OXT- 
(l-9); lower: fractionation of the pineal OXT-like peptide (peak III, fig.3A). Elution was carried out with linear 
gradients between 0.1 M sodium citrate/HCl (pH 5.9) containing 2% THF and methanol as described [19] at a flow 
rate of 1.0 ml/min. Amino acids are indicated by conventional abbreviations except cystic acid (Cys A). Component 
X represents the unknown OPT-amino acid derivative of bovine pineal AVP- and OXT-like peptides. 
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OXT-containing fractions of each extraction 
method were subjected to amino acid analysis and 
elution of 3H-labeled residues was monitored. In 
the amino acid analysis system a single radioactive 
peak co-eluted with the tyrosine standard. Elution 
of labeled components at the position of the 
unknown residue in pineal neuropeptides did not 
occur. Thus, it is unlikely that the unknown amino 
acid residue in the isolated bovine pineal AVP- and 
OXT-like peptides has been generated by exposure 
to the pineal homogenate during extraction pro- 
cedures . 
4. DISCUSSION 
From these experiments, it is concluded that the 
bovine pineal E5 preparation contains modified 
forms of AVP-(1-9) and OXT-(l-9), while AVT 
is an undetectable constituent. The modification 
possibly is a derivatized tyrosine residue located in 
residue 2 of these‘peptides. The data indicate that 
the unknown residue is different from a tyrosine 
residue alkylated or sulfated at the hydroxyl group 
of the Tyr side chain, methylated at the a-position, 
or hydroxylated at position 3 of the ring structure, 
but the identity of the residue remains unknown. 
Definite identification of the modified residue 
must await the isolation of larger quantities of the 
AVP- and OXT-like peptides from bovine pineal 
glands to allow mass-spectrometric analysis. Such 
quantities are at present not available. These 
modified forms of AVP and OXT may have 
altered biological and immunoreactive properties. 
For instance, changes in the tyrosine residue of 
AVP-(1-9) and OXT-(l-9) can alter the potency 
of the peptides in bioassays and generate an- 
tagonistic properties [22]. These altered properties 
may have led to misinterpretations in biological 
and immunological studies. It cannot be excluded 
as yet that these modified forms of AVP-( l-9) and 
OXT-( l-9) have been responsible for the AVT-like 
bioactivity of mammalian pineal gland extracts 
[ 1,8, lo]. In addition, the structural modification 
may cause loss of immunoreactivity to specific an- 
tibodies against the N-terminal positions of these 
peptides, but does not affect immunoreactivities 
with C-terminal directed antibodies [ 11,121. Thus, 
it can explain the contradictory observations of the 
presence of AVT in the pineal gland [1,3-51, and 
the findings that bioactive material in pineal ex- 
tracts behaved differently from synthetic AVP and 
OXT in the isolation procedures [I ,3]. The 
derivatization of AVP and OXT in the pineal 
gland may represent a post-translational modifica- 
tion occurring in the AVP- and OXT-containing 
fibers of the mammalian pineal organ [23], and 
suggests that an enzymatic system exists which can 
change the chemical nature of the tyrosine residue. 
This enzymatic system must be different from 
tyrosine hydroxylase which converts tyrosine into 
DOPA. Derivatized forms of AVP and OXT may 
also occur in other AVP- and OXT-containing 
areas of the brain. These peptides may have novel 
biological activities in the brain, different from the 
thus far recognized central activities of AVP-( l-9) 
and OXT-( l-9). 
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